For some cancers, such as glioma, one protein (GFAP) is given a high score with considerably lower scores for the other proteins (<50%), while in other cancers there is a continuum of importance scores, such as AML or colorectal cancer. This evidence concerns the gene GFAP and central nervous system cancer.